Brief: Biohaven Enrolls First Patient Into Phase 2/3 Trial In Early Parkinson's Disease
29/05/2025 13:04
May 29 (Reuters) - Biohaven Ltd BHVN.N: BIOHAVEN ENROLLS FIRST PATIENT INTO PHASE 2/3 TRIAL IN EARLY PARKINSON'S DISEASE, TARGETING NEUROINFLAMMATION WITH NOVEL BRAIN-PENETRANT TYK2/JAK1 INHIBITOR Source text: ID:nPn129QSGa Further company coverage: BHVN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing